Please assess the completion status of the following clinical trial:

Trial Title: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Referred to the University of Nebraska Medical Center Pre-Anesthesia Screening Clinic for preoperative evaluation.~* Above referral must be in anticipation of a non-cardiac, non-vascular surgery.~* Must have been on ACE-Inhibitor therapy for at least six weeks.~Exclusion Criteria:~* Hypotension (systolic blood pressure \< 90 or diastolic blood pressure \<60) at the time of preoperative evaluation~* Uncontrolled Hypertension (systolic blood pressure \> 150 or diastolic blood pressure \> 95) at the time of preoperative evaluation~* Surgery during which vasopressor use is anticipated (carotid endarterectomy, major abdominal operations, orthopedic oncology)~* Surgery for pathology related to vasoactive substances (carcinoid, pheochromocytoma)~* Left Ventricular ejection fraction less than 40%~* Clinical evidence of decompensated heart failure at the time of preoperative evaluation~* End-stage renal disease~* Organ transplant surgeries

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ACEI continuation (Type: EXPERIMENTAL): Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
- ACEI omission (Type: EXPERIMENTAL): Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).